Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a prospective study on the prevention of Neratinib-related diarrhea in a Chinese population, exploring the best options for reducing the incidence of neratinib-related diarrhea through either pharmacologic intervention (prophylactic antidiarrheal therapy) or non-pharmacologic intervention (dose escalation program).
Epistemonikos ID: 195c522e0257cb7ec2a27a02cffa08aea804173c
First added on: May 09, 2024